Anthracycline, cyclophosphamide, taxane, and trastuzumab-based chemotherapy is an important and highly effective chemotherapeutic regimen in HER2-positive breast cancer patients, both increasing survival duration of metastatic breast cancer and decreasing cancer recurrence and death after proper surgical treatment [12]. The gene discussed is ERBB2; the disease is breast carcinoma.